Quick Release for Accurate Blood Pressure Management Irbesartan Dispersible Tablets

• Customization: Available
• Application: Internal Medicine
• Usage Mode: For oral administration
• Model NO.: HJT-20110024
• Suitable for: Elderly, Children, Adult
• State: Solid
• Shape: Tablet
• Type: Organic Chemicals
• Pharmaceutical Technology: Chemical Synthesis
• Drug Reg./Approval No.: H20110024
• Generic Name: Irbesartan
• Strength: 150mg
• Dosage Form: Dispersible Tablets
• Packaging: 150mg*14 Tablets Per Box
• Indications: Hypertension, Diabetic Nephropathy
• Transport Package: Carton
• Specification: 150mg*14 tablets
• Trademark: HJT-Medicine
• Origin: China
• HS Code: 3004909090
• Production Capacity: 500, 000 Boxes/Month

Product Description

Product Description

Generic Name	Irbesartan Dispersible Tablets
Strength	150mg
Packaging	150mg*14 caplets/box
Indications	Irbesartan is used in the management of: Hypertension (High Blood Pressure): Irbesartan is used to treat high blood pressure either alone or in combination with other antihypertensive medications. Diabetic Nephropathy (Kidney Disease in Type 2 Diabetes): Irbesartan is indicated for the treatment of kidney disease in patients with type 2 diabetes and hypertension.

Indications:
 

• Hypertension (High Blood Pressure): Irbesartan is used to treat high blood pressure either alone or in combination with other antihypertensive medications.
• Diabetic Nephropathy (Kidney Disease in Type 2 Diabetes): Irbesartan is indicated for the treatment of kidney disease in patients with type 2 diabetes and hypertension.

Dosage:

The usually recommended initial and maintenance dose is 150 mg once daily. Diet has no impact on the administration of this medicine. Generally, irbesartan 150 mg once daily can control blood pressure over 24 hours better than 75 mg. However, for some special patients, especially those undergoing hemodialysis and patients over 75 years old, an initial dose of 75 mg can be considered. For patients whose blood pressure cannot be effectively controlled with irbesartan 150 mg once daily, the dose of this product can be increased to 300 mg, or other antihypertensive drugs can be added. In particular, the addition of diuretics such as hydrochlorothiazide has shown an additional effect. In hypertensive patients with type II diabetes, the initial treatment dose should be 150 mg once daily and increased to 300 mg once daily, which is a better maintenance dose for the treatment of nephropathy. Clinical studies have demonstrated that irbesartan benefits the kidneys of hypertensive patients with type II diabetes. In the studies, irbesartan, with the addition of other antihypertensive drugs when necessary, reduced patients' blood pressure to reach the target value.
Renal impairment: No dose adjustment of this product is required for patients with renal impairment. However, for patients undergoing hemodialysis, a low initial dose (75 mg) can be considered.
Hypovolemia: Patients with hypovolemia and/or sodium deficiency should be corrected before using this product.
Hepatic impairment: No dose adjustment of this product is required for patients with mild to moderate hepatic impairment. For patients with severe hepatic impairment, a low initial dose (75 mg) can be considered.
Elderly patients: Although a starting dose of 75 mg can be considered for the elderly over 75 years old, usually no dose adjustment is required for elderly patients.
Children: The safety and efficacy of irbesartan in children have not been established.

 

Adverse Effects:

The incidence rates of the adverse reactions listed below are defined as follows:

Very common (≥1/10); common (≥1/100); uncommon (≥1/1000, <1/100); very rare (<1/10,000).

For hypertension: In placebo-controlled trials of hypertensive patients abroad, there was no difference in the overall incidence of adverse events between the irbesartan group (56.2%) and the placebo group (56.5%). The incidence of treatment discontinuation due to clinical or laboratory adverse events was lower in the irbesartan treatment group (3.3%) than in the placebo group (4.5%). The occurrence of adverse events was not related to the dose (within the recommended dose range), gender, age, race, or treatment duration.

 

Medication use in pregnant and lactating women:

 

Pregnancy: As a precautionary measure, it is advisable not to use this product during the first trimester of pregnancy. Appropriate alternative treatments should be switched to before planned pregnancy. From the 4th to the 9th month of pregnancy, substances that act directly on the renin-angiotensin system can cause renal failure in fetuses and neonates, abnormal fetal cranial development, and fetal death. Therefore, this product is contraindicated in pregnant women from the 4th to the 9th month of pregnancy. If pregnancy is detected, this product should be discontinued as soon as possible. If treatment has been carried out for a long time due to negligence, ultrasound examinations of the skull and renal function should be performed.

 

Company Profile

HENG JING TANG PHARMACEUTICAL CO., LTD. is a prominent pharmaceutical company based in Anhui Province, China. Established with a commitment to the research, development, manufacturing, and marketing of high-quality pharmaceutical products, the company specializes in both traditional Chinese medicine (TCM) and modern pharmaceutical solutions. Hengjingtang integrates modern technology with traditional Chinese medicine practices to create innovative, effective products aimed at improving public health.

Core Business Areas
The company is involved in a wide range of pharmaceutical sectors, including:

• Traditional Chinese Medicine (TCM): Specializing in the production and sale of Chinese herbal medicine and TCM-based formulations.
• Prescription Drugs: Development and manufacturing of prescription drugs, focusing on various therapeutic areas, including cardiovascular diseases, diabetes, and other chronic conditions.
• Over-the-Counter (OTC) Products: Producing non-prescription products such as supplements and health-promoting medicines.
• Research & Development: Hengjingtang invests heavily in R&D, continually striving to improve existing products and develop new formulations. The company is involved in clinical research to ensure the safety and efficacy of its products.

Manufacturing and Quality Control
Hengjingtang operates state-of-the-art manufacturing facilities that comply with national and international standards, including GMP (Good Manufacturing Practices) certification. The company adheres to rigorous quality control processes to ensure that all products meet the highest standards of safety, quality, and efficacy.

Commitment to Innovation
Hengjingtang places a strong emphasis on scientific research and innovation. The company collaborates with research institutions and universities to advance pharmaceutical technologies and improve the effectiveness of its product lines. Hengjingtang's dedication to innovation ensures that it can continuously meet the evolving healthcare needs of its customers.